No clinical data are available to date regarding the possible role of FGF21 in OA prevention or progress; however, the proposed role of FGF21 agonists in treating liver steatosis and other metabolic diseases might be relevant for OA of metabolic origin or OA with disease comorbidities [100]. This evidence concerns the gene FGF21 and metabolic disease.